May 28, 2017/Cancer/News & Insight

ASCO 2017 – Saturday, June 3

Please join our staff as we participate or present in the following oral and poster presentations at the 2017 ASCO Annual Meeting

#ASCO_650x450

Saturday, June 3

Advertisement

Cleveland Clinic is a non-profit academic medical center. Advertising on our site helps support our mission. We do not endorse non-Cleveland Clinic products or services. Policy

8:00 AM – 9:15 AM
Location: S404

EDUCATION SESSION: mHealth: Mobile Technologies to Virtually Bring the Patient into Oncology Practice

8:00 AM – 8:20 AM
Technological Solutions to Improve Efficiency
Nathan A. Pennell, MD, PhD – Speaker

8:00 AM – 11:30 AM
Location: Hall A

POSTER SESSION: Gastrointestinal (Noncolorectal) Cancer
Abstract TPS4152: SWOG S1505: A randomized phase II study of perioperative mFOLFIRINOX vs. gemcitabine/nab-paclitaxel as therapy for resectable pancreatic adenocarcinoma
Poster Board: #133b
Davendra Sohal, MD, MPH – First Author

8:45 AM – 9:30 AM
Location: Member Lounge Room S501

TRAINEE & EARLY CAREER ONCOLOGIST
Contract Negotiations
Jame Abraham, MD

1:15 PM – 4:45 PM
Location: Hall A

Advertisement

POSTER SESSION: Tumor Biology

Abstract 11518: Changes in computer extracted features of vessel tortuosity on CT scans post-treatment in responders compared to non-responders for non-small cell lung cancer on immunotherapy
Poster Board: #218
Discussed at the Poster Discussion Session on Saturday, June 3, 2017, 4:45 PM – 6:00 PM, at S406
Vamsidhar Velcheti, MD – First Author

Abstract 11547: Pre-treatment hematological markers as a predictive biomarker for survival in patients with non-small cell lung cancer treated with nivolumab
Poster Board: #247
Pradnya Dinkar Patil, MD – First Author

Abstract 11552: Tetrahydrouridine-decitabine for non-cytotoxic epigenetic therapy of NSCLC to enhance immunotherapeutic effect of anti-PD1 in vivo
Poster Board: #252
Kai Kang, PhD – First Author

Abstract 11566: Computer extracted measurements of vessel tortuosity on baseline CT scans to predict response to nivolumab immunotherapy for non-small cell lung cancer
Poster Board: #266
Monica Khunger, MD – First Author

1:15 PM – 4:45 PM
Location: Hall A

POSTER SESSION: Patient and Survivor Care
Abstract 10063: What do social media-savvy cancer survivors tell us about the completeness of survivorship care plans?
Poster Board: #52
Diane Mary Radford, MD, FACS, FRCSEd – First Author

Advertisement

3:00 PM – 4:15 PM
Location: Hall D2

POSTER DISCUSSION SESSION: Lung Cancer—Non-Small Cell Metastatic

3:18 PM – 3:30 PM
Three Faces of IO: Efficacy, Toxicity, Cost
Vamsidhar Velcheti, MD – Discussant
Discussing Abstract(s): 9011, 9012, 9013

Related Articles

adverse events from immune checkpoint inhibitors
December 21, 2023/Cancer/News & Insight
Managing Hormone Dysfunction-Related Adverse Events of Immunotherapy for Breast Cancer Treatment

Timing and type of side effects differ greatly from chemotherapy

23-CNR-4274330-CQD-Hero-650×450
October 18, 2023/Cancer/News & Insight
Cleveland Clinic Lerner Research Institute to Host Head & Neck Cancer CME Symposium

Sessions explore treatment advances and multidisciplinary care

23-CNR-4210971-CQD-Hero-650×450 Dr Yu
October 9, 2023/Cancer/News & Insight
Pathway Cross-Talk Suggests New Approach to Glioblastoma Treatment

New research from Cleveland Clinic helps explain why these tumors are so refractory to treatment, and suggests new therapeutic avenues

23-CNR-4071967-CQD-Hero-650×450 scan for triple-negative breast cancer case study
September 19, 2023/Cancer/News & Insight
Patient With Stage 4 Triple-Negative Breast Cancer in Remission 10 Years After Initial Diagnosis

Combination of olaparib and carboplatin results in complete durable response for a patient with BRCA2 and “BRCAness” mutations

23-CNR-4140381-CQD-Hero-650×450 eye toxicities in cancer treatment
September 7, 2023/Cancer/News & Insight
Eye Toxicities More Prevalent Side Effect of Cancer Treatment Than Previously Understood

Early communication between oncologists and ophthalmologist warranted

23-CNR-4185077-CQD-Hero-650×450
August 31, 2023/Cancer/News & Insight
CME Program Takes Multidisciplinary Approach to Colorectal Cancer

Case-based course delves into latest treatment approaches

outreach to underserved communities
June 2, 2023/Cancer/News & Insight
Focus Groups Amplify the Voices of Black Congregants about Disparities in Clinical Trials

Long-term relationship building and engagement key to gaining community trust

Ad